
Maxidim250 mg/via
Beximco Pharmaceuticals Ltd.
Lower Respiratory Tract Infections Ceftazidime Pentahydrate is an established, guideline-supported treatment for lower respiratory tract infections and more.
Ceftazidime Pentahydrate is an established, guideline-supported treatment for lower respiratory tract infections, including hospital-acquired pneumonia (including ventilator-associated pneumonia) caused by susceptible organisms such as Pseudomonas aeruginosa, Klebsiella pneumoniae, and other susceptible gram-negative bacteria, administered under medical or hospital supervision.
Ceftazidime Pentahydrate is an established treatment for complicated and uncomplicated urinary tract infections caused by susceptible organisms, including infections due to Pseudomonas aeruginosa and other susceptible gram-negative pathogens.
Ceftazidime Pentahydrate is established therapy for complicated intra-abdominal infections (including peritonitis) caused by susceptible organisms, generally used in combination with an agent active against anaerobic bacteria, since Ceftazidime Pentahydrate itself has little activity against anaerobes.
Ceftazidime Pentahydrate is an established treatment for skin and skin-structure infections caused by susceptible organisms.
Ceftazidime Pentahydrate is an established treatment for bone and joint infections caused by susceptible organisms.
Ceftazidime Pentahydrate is an established treatment for gynecologic infections caused by susceptible organisms.
Ceftazidime Pentahydrate is an established treatment for bacteremia/septicemia caused by susceptible organisms.
Ceftazidime Pentahydrate is an established treatment for meningitis and other central nervous system infections caused by susceptible organisms, reflecting its ability to penetrate the blood-brain barrier, particularly when the meninges are inflamed; it is used under specialist/hospital direction.
Ceftazidime Pentahydrate has notable antipseudomonal activity and is a guideline-recognized option for serious infections caused by Pseudomonas aeruginosa, including in patients with cystic fibrosis or febrile neutropenia, often as part of combination regimens for the most severe presentations.
Ceftazidime Pentahydrate is a guideline-recognized option for empiric monotherapy or combination therapy in febrile neutropenic patients at risk of serious gram-negative infection, used under specialist oncology/infectious-disease direction.
Ceftazidime Pentahydrate is administered only by or under the supervision of a qualified healthcare professional in a hospital or clinical setting, as it is given by intravenous or intramuscular injection.
The dose, route, and frequency of Ceftazidime Pentahydrate depend on the site and severity of infection, the causative organism (where known), and the patient's age, weight, and renal function. Ceftazidime Pentahydrate is given by intravenous or intramuscular injection only, under medical or hospital supervision; the regimens below reflect commonly cited, label- and guideline-based dosing and must be individualized by a qualified healthcare professional. Take Ceftazidime Pentahydrate exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.
Ceftazidime Pentahydrate is contraindicated in patients with a known history of a serious hypersensitivity reaction (e.g., anaphylaxis) to Ceftazidime Pentahydrate, to any other cephalosporin-class antibiotic, or to any component of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.